Navigation Links
Alma Lasers Announces Proposed Initial Public Offering
Date:1/3/2008

BUFFALO GROVE, Ill., Jan. 3 /PRNewswire/ -- Alma Lasers Ltd. ("Alma Lasers") announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to its proposed underwritten initial public offering of its ordinary shares.

The initial public offering is expected to consist of newly issued shares being offered by Alma Lasers and secondary shares offered by certain stockholders. In addition, Alma Lasers expects to grant the underwriters an option to purchase additional ordinary shares to cover over-allotments, if any.

Citigroup Global Markets Inc. and UBS Investment Bank will serve as joint bookrunning managers, William Blair & Company, L.L.C. will serve as lead manager, and Jefferies & Company, Inc. will serve as co-manager for the proposed offering.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement.

Once available, a preliminary prospectus relating to these securities may be obtained by contacting Citigroup Global Markets Inc., Brooklyn Army Terminal, 140 58th Street, Brooklyn, New York 11220, Attn: Prospectus Department or UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, New York 10171.

About Alma Lasers

Alma Lasers is a global medical technology company that designs, develops, manufactures and markets laser, intense pulsed light and radiofrequency based aesthetic treatment devices that can be used to treat a broad range of skin types and indications. Alma Lasers believes that its products have typically been at the forefront of technological development in the energy-based aesthetic treatment system market. Since commercializing its first aesthetic treatment system in 2002, Alma Lasers has introduced eight systems that work in combination with approximately 19 handpieces. Alma Lasers' mission is to leverage its technical expertise and in-depth understanding of practitioners' needs in order to provide modular, cost-effective and high performance designs that enable medical practitioners to confidently offer safe, effective and profitable aesthetic treatments to their patients.

Alma Lasers. Wellbeing Through Technology.

Contact:

William Bruckner

Vice President, Global Marketing

Tel. 224.377.2010

billb@almalasers.com

Shai Halivni

Vice President, General Counsel

Tel: 224.377.2008

shaih@almalasers.com


'/>"/>
SOURCE Alma Lasers Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alma Lasers Answers Lumenis Complaint
2. Smart Balance Announces Conversion of Convertible Preferred Stock
3. IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives
4. MQ Associates, Inc. Announces Cash Tender Offer for 121/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Related Consent Solicitation
5. Heska Announces Amended Agreement With AgriLabs
6. Versus Technology Announces Fourth Quarter Results
7. FASgen Announces New Research Discoveries in Lung Cancer
8. Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator
9. KV Pharmaceutical Company Announces NYSE Listing Extension
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
11. Transition Therapeutics Announces Appointment of Vice-President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take ... goals to better one’s life through God. “The Trials I Face to Receive God’s ... wrong places, found a love for writing. Green feels that expressing his feelings through ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. ... work and rolled up their sleeves to help with relief efforts. The team picked ... process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young ... creation of published author, Jeanine Liston, a busy mother of five who used her time ... been writing this book for over twenty years. It was a way to give ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Monique”: ... into uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned ... Since then Crispi has been involved in real estate and cooking. , “The ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... that Mike Rice , President and CEO, will be ... Rodman & Renshaw 19 th Annual Global ... time (12:25 p.m. Pacific time). The conference is being held ...
Breaking Medicine Technology: